eIF2β, a subunit of translation‐initiation factor EIF2, is a potential therapeutic target for non‐small cell lung cancer
暂无分享,去创建一个
K. Coombes | J. Minna | L. Girard | L. Byers | M. Kondo | Y. Hasegawa | Y. Sekido | Mitsuo Sato | I. Tanaka | M. Morise | Ayako Miyazawa | T. Hase | Daiki Goto | N. Yogo | Toshio Kato | J. Heymach | Tomohiko Kakumu
[1] N. Setterblad,et al. Deletion of eIF2β lysine stretches creates a dominant negative that affects the translation and proliferation in human cell line: A tool for arresting the cell growth , 2017, Cancer biology & therapy.
[2] K. Coombes,et al. Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer , 2017, Cancer science.
[3] Mingming Jia,et al. COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..
[4] R. Morgan,et al. Ran GTPase promotes cancer progression via Met receptor-mediated downstream signaling , 2016, Oncotarget.
[5] John D. Minna,et al. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer , 2016, Nature.
[6] T. Umehara,et al. Crystal structure of eukaryotic translation initiation factor 2B , 2016, Nature.
[7] David Petersen,et al. An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[8] A. Koromilas. Roles of the translation initiation factor eIF2α serine 51 phosphorylation in cancer formation and treatment. , 2015, Biochimica et biophysica acta.
[9] Nobhojit Roy,et al. The Global Burden of Cancer 2013. , 2015, JAMA oncology.
[10] Michael L. Gatza,et al. An integrated genomics approach identifies drivers of proliferation in luminal subtype human breast cancer , 2014, Nature Genetics.
[11] Kwok-Kin Wong,et al. Non-small-cell lung cancers: a heterogeneous set of diseases , 2014, Nature Reviews Cancer.
[12] John D. Minna,et al. Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations , 2013, Molecular Cancer Research.
[13] Sanjeev Gupta,et al. The eIF2α kinases: their structures and functions , 2013, Cellular and Molecular Life Sciences.
[14] Osama Sharaf Eldin,et al. Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways , 2011, Clinical Cancer Research.
[15] Jian-Ting Zhang,et al. Translational control gone awry: a new mechanism of tumorigenesis and novel targets of cancer treatments. , 2011, Bioscience reports.
[16] Jason D. Heaney,et al. Deletion of eIF2beta suppresses testicular cancer incidence and causes recessive lethality in agouti-yellow mice. , 2009, Human molecular genetics.
[17] Brad T. Sherman,et al. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.
[18] J. Minna,et al. A Translational View of the Molecular Pathogenesis of Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[19] Xiaomei Ma,et al. Global Burden of Cancer , 2006, The Yale journal of biology and medicine.
[20] J. Minna,et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. , 2006, Cancer research.
[21] J. Pollack,et al. Immortalization of Human Bronchial Epithelial Cells in the Absence of Viral Oncoproteins , 2004, Cancer Research.
[22] A. Fraire,et al. Expression of eukaryotic translation initiation factors 4E and 2α is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung , 2001, Cancer.
[23] A. Jemal,et al. Lung Cancer Statistics. , 2016, Advances in experimental medicine and biology.
[24] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.